Following two important announcements, we spoke yesterday with Clinuvel Non-Executive Director, Dr Roger Aston. We asked Dr Aston to draw upon his experiences within the international pharmaceutical and life sciences industries to provide context to the company’s news.
Listen to the entire webcast here
Related Posts:
Tags: clinuvel, Erythropoietic Protoporphyria, Italy, Scenesse, scenesse
This entry was posted
on Wednesday, May 19th, 2010 at 12:03 pm and is filed under Clinuvel News, Pharma Development, Scenesse.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
